REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

Group 1 - REGENXBIO Inc. will host a webcast to discuss interim functional data from the Phase I/II AFFINITY DUCHENNE® trial of RGX-202, a gene therapy for Duchenne muscular dystrophy [1] - The webcast will feature principal investigator Aravindhan Veerapandiyan, M.D., from Arkansas Children's Hospital [1] - The event is scheduled for June 5, 2025, at 8:00 a.m. EDT, and will be accessible via REGENXBIO's website [2] Group 2 - REGENXBIO is a biotechnology company focused on gene therapy, founded in 2009, and has pioneered AAV gene therapy [3] - The company is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for Duchenne muscular dystrophy [3] - REGENXBIO's investigational therapies have the potential to significantly impact healthcare delivery for millions [3]